TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 19533165
Drug: Citalopram (CITAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (CITAL 2 x 10 mg)
Study: 19533165
Drug: Placebo (PLA:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (PLA: lactose 2 x 10 mg)
Study: 17207172
Drug: EGF (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: EGF (10 microg/g) in 0.1% silver sulfadiazine cream
Study: 17207172
Drug: 0.1% silver
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.1% silver sulfadiazine cream alone
Study: 12075760
Drug: AZM 10
Normalized name: Azmiro
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZM 10 mg/kg/day
Study: 12075760
Drug: AZM 20
Normalized name: Azmiro
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZM 20 mg/kg/day
Study: 9793623
Drug: Klimonorm (Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Klimonorm (Test preparation)
Study: 9793623
Drug: Klimonorm (Test
Approvals — FDA: no, EMA: no, PMDA: no
Description: Klimonorm (Test preparation) and Reference preparation
Study: 2941493
Drug: Recombinant alpha-2
Normalized name: (2S)-alpha-2-Amino-4-methylvaleric acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Recombinant alpha-2 interferon (rIFN-alpha 2) at a dosage of 2 X 10(6) units, administered three times per week for one year
Study: 29843276
Drug: Conventional therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Conventional therapy (Control Group)
Study: 26638130
Drug: Paracetamol 1
Normalized name: Paracetamol 1 g oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol 1 g four times a day for 5 days
Study: 23886272
Drug: Coenzyme Q10
Normalized name: Coenzyme Q10
DrugBank: Ubidecarenone (DB09270)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Coenzyme Q10 (CoQ10) treatment in FM patients
Study: 21481958
Drug: Levosimendan (0.3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levosimendan (0.3 mg/kg/min, administered weekly for 6h over 6 months)
Study: 21481958
Drug: Dobutamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (10 mg/kg/min, administered weekly for 6h over 6 months)
Study: 21481958
Drug: Dobutamine (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dobutamine (10 mg/kg/min) + Levosimendan (0.2 mg/kg/min, administered weekly for 6h over 6 months)
Study: 2404837
Drug: Crossover to
Normalized name: Wong To Yick
Approvals — FDA: no, EMA: no, PMDA: no
Description: Crossover to the other platinum compound (carboplatin if initially treated with cisplatin, and vice versa)
Study: 2404837
Drug: Rechallenged with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rechallenged with the same drug (cisplatin or carboplatin)
Study: 7304657
Drug: Single-dose cefaclor
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefaclor (2 g orally)
Study: 7304657
Drug: Multidose cefaclor
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidose cefaclor (250 mg orally three times a day for 10 days)
Study: 7304657
Drug: Single-dose cefaclor
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single-dose cefaclor (2 g orally) with ACB test (less inclusive criteria)
Study: 7304657
Drug: Multidose cefaclor
Normalized name: Cefaclor
DrugBank: Cefaclor (DB00833)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Multidose cefaclor (250 mg orally three times a day for 10 days) with ACB test (less inclusive criteria)
Study: 28780479
Drug: Androgen deprivation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Androgen deprivation therapy (ADT) + docetaxel (D)
Study: 17223870
Drug: Topical methyl
Normalized name: methylal
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical methyl aminolaevulinate (MAL) cream (160 mg g(‐1)) applied for 3 hours
Study: 17223870
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied for 3 hours
Study: 7610529
Drug: Doxycyclin 2
Normalized name: Doxycycline
DrugBank: Doxycycline (DB00254)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Doxycyclin 2 x 100 mg p. o. for at least 14 days or Cefuroxim 2 x 500 mg if contraindicated
Study: 7610529
Drug: Ceftriaxon 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ceftriaxon 1 x 2‐‐2 x 2 g i. v. or Cefotaxim 3 x 2 g i. v. for at least 14 days
Study: 2782043
Drug: L-dopa 100
Normalized name: L-DOPA 100 MG Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-dopa 100 mg plus benserazide 25 mg
Study: 959118
Drug: Killed influenza
Normalized name: INFLUENZA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Killed influenza vaccine given by injection
Study: 959118
Drug: Selective vaccination
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selective vaccination for high-risk groups (e.g., elderly, key workers)
Study: 26065919
Drug: P2-VP8 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2-VP8 vaccine (10, 30, or 60 μg)
Study: 26065919
Drug: P2-VP8 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2-VP8 vaccine (60 μg)
Study: 26065919
Drug: P2-VP8 vaccine
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: P2-VP8 vaccine (any dose)
Study: 22924571
Drug: GH (dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: GH (dose based on IGF-I titration algorithm; n = 114)
Study: 21422084
Drug: IVIg (0.75
Approvals — FDA: no, EMA: no, PMDA: no
Description: IVIg (0.75 g/kg)
Study: 19527189
Drug: Local oestrogen
Normalized name: estrogens
Approvals — FDA: no, EMA: no, PMDA: no
Description: Local oestrogen therapy
Study: 19527189
Drug: Drugs enhancing
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drugs enhancing nitric oxide or vasoactive intestinal polypeptide
Study: 19527189
Drug: Phosphodiesterase inhibitors
Normalized name: Phosphodiesterase inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phosphodiesterase inhibitors
Study: 19527189
Drug: Local administration
Normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Local administration of dihydroepiandrosterone
Study: 14722892
Drug: Lopinavir/ritonavir 800/200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lopinavir/ritonavir 800/200 mg once daily
Study: 11139311
Drug: Oral paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral paclitaxel (120 mg/m²) with GF120918 (1000 mg)
Study: 11139311
Drug: Oral paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Oral paclitaxel (120 mg/m²) with CsA (previous study)
Study: 11139311
Drug: Intravenous paclitaxel
Normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Intravenous paclitaxel (175 mg/m²)
Study: 9596394
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 100 BTA U into the tibialis posterior muscle, followed by ankle-foot taping (group B)
Study: 9596394
Drug: Injection of
Normalized name: purified protein derivative of tuberculin Injectable Solution [Aplisol]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Injection of 190 to 320 BTA U into several calf muscles (group A)
Study: 7889428
Drug: Fluticasone Propionate
Normalized name: Fluticasone Propionate
DrugBank: Fluticasone propionate (DB00588)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Fluticasone Propionate Aqueous Nasal Spray (FPANS) 200 micrograms once daily
Study: 7889428
Drug: Terfenadine tablets
Normalized name: terfenadine Oral Tablet
DrugBank: Terfenadine (DB00342)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Terfenadine tablets (60 mg) twice daily
Study: 3498406
Drug: 1.5 mg
Normalized name: boron 1.5 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg . kg‐1 propofol
Study: 3498406
Drug: 2 mg
Normalized name: iodine 2 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mg . kg‐1 methohexitone
Study: 3498406
Drug: Propofol 1.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 1.5 mg . kg‐1 with fentanyl 1.5 micrograms . kg‐1
Study: 3498406
Drug: Propofol 2
Normalized name: propofol 20 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol 2 micrograms . kg‐1 with vecuronium 0.1 mg . kg‐1
Study: 3498406
Drug: Methohexitone 2
Normalized name: Methohexitone
DrugBank: Methohexital (DB00474)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methohexitone 2 mg . kg‐1
Study: 19549706
Drug: Sunitinib (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunitinib (50 mg/day for 4 weeks, followed by 2 weeks off)
Study: 19549706
Drug: Interferon-alpha (9
Approvals — FDA: no, EMA: no, PMDA: no
Description: Interferon-alpha (9 million units s.c. injection three times/week)
Study: 16512083
Drug: Explicit, systematic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Explicit, systematic reading intervention in Spanish for treatment group (daily for 50 min)
Study: 12649125
Drug: Standard therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard therapy plus recombinant surfactant protein C surfactant (Venticute) given four times over 24 hours
Study: 30883859
Drug: Treatment switched
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment switched at an HIV-RNA threshold of 1000 copies/ml
Study: 26772449
Drug: Daily zinc
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily zinc supplement
Study: 23978948
Drug: Fentanyl 3
Normalized name: FENTANYL 37.5MCG/HR PATCH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fentanyl 3 μg/ml
Study: 17472485
Drug: 300 mg/1.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg/1.2 g NT-GA combination
Study: 17472485
Drug: 600 mg/2.4
Approvals — FDA: no, EMA: no, PMDA: no
Description: 600 mg/2.4 g NT-GA combination
Study: 12575373
Drug: Fluticasone inhalation
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone inhalation combined with Jinacon (JNC)
Study: 12575373
Drug: Fluticasone inhalation
Normalized name: fluticasone Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone inhalation alone
Study: 9649143
Drug: Tamoxifen 20
Normalized name: tamoxifen 20 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tamoxifen 20 mg day(-1)
Study: 2656777
Drug: Tonazocine mesylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonazocine mesylate 4 mg
Study: 2656777
Drug: Tonazocine mesylate
Normalized name: mesylate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tonazocine mesylate 8 mg
Study: 1080959
Drug: Pharmacologic doses
Normalized name: COPD pharmacologic substance
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacologic doses of steroids administered early in the shock state (within the first hour) for periods of less than forty-eight hours
Study: 28359172
Drug: Control (oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (oral airway only)
Study: 25933111
Drug: Cisplatin/Gemcitabine (up
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisplatin/Gemcitabine (up to six cycles; cisplatin 75 mg/m2 [d1]; gemcitabine 1000 mg/m2 [d1,8])
Study: 16009445
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg/day for 12 weeks
Study: 16009445
Drug: Rosiglitazone 4
Normalized name: rosiglitazone 4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rosiglitazone 4 mg/day followed by Fenofibrate 200 mg/day for an additional 12 weeks
Study: 14959471
Drug: Standard drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drugs plus bicycle exercise (group 1)
Study: 14959471
Drug: Standard drugs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard drugs only (group 2)
Study: 8442964
Drug: IV ondansetron
Normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: IV ondansetron (two 8 mg doses 8 hours apart)
Study: 20850097
Drug: Aspirin 100
Normalized name: aspirin 100 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin 100 mg and Clopidogrel 75 mg for 6 months
Study: 10705425
Drug: Subcutaneous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Subcutaneous lidocaine around the sheath site
Study: 9373656
Drug: 3 days
Normalized name: Transderm Scop 1mg/3 days Transdermal System
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 days treatment with Quinimax® (10 mg/kg twice daily)
Study: 9373656
Drug: 5 days
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5 days treatment with Quinimax® (10 mg/kg twice daily)
Study: 9373656
Drug: 7 days
Normalized name: ZINGIBER OFFICINALE (GINGER) ROOT OIL 0.006 mg in 30 mg TOPICAL LIQUID [JAYSUING 7 Days Nail Fungus Treatment]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7 days treatment with Quinimax® (10 mg/kg twice daily)
Study: 29544928
Drug: Diuretic response
Normalized name: Besponsa
DrugBank: Inotuzumab ozogamicin (DB05889)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Diuretic response
Study: 23050526
Drug: Policy implementation
Normalized name: Polivy
DrugBank: Polatuzumab vedotin (DB12240)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Policy implementation (discontinuation of additional payments for preventable infections)
Study: 18511530
Drug: Intraarticular corticosteroid
Normalized name: abiraterone and corticosteroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular corticosteroid (1 mL, 40 mg methylprednisolone acetate) followed by a 12‐week comprehensive home exercise programme
Study: 18511530
Drug: Intraarticular serum
Normalized name: Serum, horse
DrugBank: Serum, horse (DB14613)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intraarticular serum physiologic (1 mL solution of 0.9% sodium chloride) followed by a 12‐week comprehensive home exercise programme
Study: 9049962
Drug: Intensive chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive chemotherapy (CCG-1800 series, 1989-1994)
Study: 9049962
Drug: Moderate intensity
Approvals — FDA: no, EMA: no, PMDA: no
Description: Moderate intensity chemotherapy (CCG-100 series, 1983-1989)
Study: 6129091
Drug: Pafenolol (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pafenolol (5 mg)
Study: 6129091
Drug: Pafenolol (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pafenolol (7.5 mg)
Study: 6129091
Drug: Metoprolol (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (15 mg)
Study: 6129091
Drug: Terbutaline (inhaled
Approvals — FDA: no, EMA: no, PMDA: no
Description: Terbutaline (inhaled in increasing doses)
Study: 24332587
Drug: Supraperiosteal injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supraperiosteal injection of methylprednisolone
Study: 24332587
Drug: Oral tablets
Normalized name: digoxin 0.1875 MG Oral Tablets
DrugBank: Sodium citrate (DB09154)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets of methylprednisolone
Study: 24332587
Drug: Intravenous (i.v.)
Normalized name: immunoglobulins, intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous (i.v.) injection of methylprednisolone
Study: 11093967
Drug: Red wine
Normalized name: Red wine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Red wine (60 g ethanol) with a standard dinner
Study: 6356605
Drug: Verbascan (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verbascan (10 mg three times daily)
Study: 25669832
Drug: Concurrent regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Concurrent regimen with gefitinib (250 mg) and carboplatin/pemetrexed (AUC = 6 and 500 mg/m2; 3-weekly)
Study: 25669832
Drug: Sequential alternating
Normalized name: yellow fever virus strain 17D-204 live antigen
DrugBank: Yellow fever vaccine (DB10805)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sequential alternating regimen with gefitinib (250 mg) and carboplatin/pemetrexed (AUC = 6 and 500 mg/m2; 3-weekly)
Study: 21811060
Drug: Pomegranate juice
Normalized name: pomegranate juice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pomegranate juice (120 ml)
Study: 16796705
Drug: Levodopa (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa (100 mg single dose)
Study: 26953770
Drug: Balloon Rectal
Normalized name: CATHETER,BALLOON
Approvals — FDA: no, EMA: no, PMDA: no
Description: Balloon Rectal Channel Catheter (BRCC)
Study: 24530403
Drug: AV7909 with
Approvals — FDA: no, EMA: no, PMDA: no
Description: AV7909 with low-dose (0.25mg/dose) CPG 7909
Study: 24530403
Drug: AVA (Anthrax
Approvals — FDA: no, EMA: no, PMDA: no
Description: AVA (Anthrax Vaccine Adsorbed, no CPG 7909)
Study: 20412605
Drug: Multiple-micronutrient supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Multiple-micronutrient supplementation (20 mg Fe and 400 microg folic acid)
Study: 18603822
Drug: Acarbose 300
Normalized name: Acarbose
DrugBank: Acarbose (DB00284)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acarbose 300 mg/day for 12 months
Study: 15823212
Drug: Interferon-alpha 6
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 6 million units (6-MU) thrice weekly for 24 weeks
Study: 15823212
Drug: Interferon-alpha 3
Normalized name: Interferon alpha-2B
DrugBank: Interferon alfa-2b (DB00105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Interferon-alpha 3 million units (3-MU) thrice weekly for 24 weeks
Study: 12377843
Drug: Inhaled flunisolide
Normalized name: flunisolide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled flunisolide via metered‐dose inhaler (250 micro g per activation) eight puffs bid
Study: 10357386
Drug: ddC/ZDV (zalcitabine
Approvals — FDA: no, EMA: no, PMDA: no
Description: ddC/ZDV (zalcitabine 0.75 mg and zidovudine 200 mg every 8 h)
Study: 10357386
Drug: SQV/ZDV (saquinavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV/ZDV (saquinavir 600 mg and zidovudine 200 mg every 8 h)
Study: 10357386
Drug: SQV/ddC/ZDV (saquinavir
Approvals — FDA: no, EMA: no, PMDA: no
Description: SQV/ddC/ZDV (saquinavir 600 mg, zalcitabine 0.75 mg and zidovudine 200 mg every 8 h)
Study: 7584529
Drug: 50 micrograms
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 micrograms ovine CRH administered intravenously as a bolus every hour from 0.00 hrs. to 6.00 hrs.
Study: 31490257
Drug: Intravenous lidocaine
Normalized name: Lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intravenous lidocaine (1.5 mg/kg bolus dose followed by a 2 mg/kg/h continuous infusion during the intraoperative period, continued for 1 hour postsurgery)
Study: 24610631
Drug: Low-dose iloprost
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose iloprost (30 ng/kg/min)
Study: 24610631
Drug: High-dose iloprost
Normalized name: Iloprost
DrugBank: Iloprost (DB01088)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: High-dose iloprost (50 ng/kg/min)
Study: 21448165
Drug: sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib plus IL‐2 (400 mg twice daily + 4.5 MIU five times per week for 6 in every 8 weeks)
Study: 21448165
Drug: sorafenib plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: sorafenib plus IL‐2 (initial higher dose)
Study: 15208494
Drug: Radioiodine therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Radioiodine therapy (400 MBq)
Study: 9494430
Drug: Water-cooled jacket
Approvals — FDA: no, EMA: no, PMDA: no
Description: Water-cooled jacket with inlet water temperature maintained at 10-12 degrees C and flow rates of 2.6 +/- 0.3, 4.3 +/- 0.3, and 5.1 +/- 0.3 l/h.
Study: 2847522
Drug: Enalaprilat (1.25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalaprilat (1.25 or 5.0 mg)
Study: 2847522
Drug: Furosemide (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Furosemide (40 or 80 mg)
Study: 30866895
Drug: Personalised texting
Approvals — FDA: no, EMA: no, PMDA: no
Description: Personalised texting intervention (CRA summary letter + 24 weekly personalised text messages)
Study: 30866895
Drug: Non-personalised texting
Normalized name: Tavist Non-Sedating
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non-personalised texting intervention (non-personalised letter + 24 weekly non-personalised text messages)
Study: 28337893
Drug: Symbiotic treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbiotic treatment (Lactobacillus acidophilus NCFM, Bifidobacterium lactis, and fructo‐oligosaccharides) as adjunctive therapy
Study: 28337893
Drug: Standard pharmacological
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard pharmacological treatment (nasal corticosteroid, oral antihistamine, and isotonic saline)
Study: 10779420
Drug: Subcutaneous bolus
Normalized name: subcutaneous bolus insulin patch pump, 200 unit, disposable 2 unit MISCELL EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous bolus injection of deferoxamine
Study: 10779420
Drug: Subcutaneous continuous
Normalized name: Ivy Dry Super Continuous Spray
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subcutaneous continuous infusion of deferoxamine
Study: 10779420
Drug: Long-term efficacy
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term efficacy of bolus injection
Study: 1594552
Drug: Pancrex M
Normalized name: Coenzyme M
DrugBank: Coenzyme M (DB09110)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pancrex M (newer microsphere preparation)
Study: 3976336
Drug: Naloxone (0.01
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.01 mg/kg, i.m.)
Study: 31347692
Drug: Control (FeSO4,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control (FeSO4, 60 mg Fe/kg)
Study: 28531643
Drug: LNS (lipid-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNS (lipid-based nutrient supplements)
Study: 28531643
Drug: LNS-VM (lipid-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNS-VM (lipid-based nutrient supplements with vitamins and minerals)
Study: 24695878
Drug: Fluoroscopic cervical
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluoroscopic cervical paramidline interlaminar epidural steroid injection (ESI)
Study: 22278649
Drug: High-intensity stretch
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-intensity stretch home mechanical therapy (n = 11)
Study: 22278649
Drug: Low-intensity stretch
Normalized name: Mederma Stretch Mark Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Low-intensity stretch home mechanical therapy (n = 9)
Study: 12586131
Drug: Aspirin bolus
Normalized name: ASPIRIN 16 g ORAL TABLET [Aspirin Bolus]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aspirin bolus (500 mg)
Study: 12586131
Drug: Ticlopidin (500
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticlopidin (500 mg loading dose)
Study: 367795
Drug: Paracetamol (0.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paracetamol (0.5 g X 4 for 3 days)
Study: 367795
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acetylsalicylic acid (0.5 g X 4 for 3 days)